ADVANCED CLINICAL
PSYCHOPHARMACOLOGY & COMPREHENSIVE
BOARD REVIEW EXAMINATION
200 Clinical Questions with In-Depth Rationales
Focus: Schizophrenia, Metabolic Comorbidities, Antipsychotic Switch
Strategies, and Psychopharmacology
PRIMARY CLINICAL VIGNETTE
A 52-year-old male with chronic schizophrenia and type 2 diabetes
mellitus is currently taking olanzapine 20 mg daily with suboptimal
symptom control and a 15-kg weight gain (HbA1c increased from
7.2% to 8.6%). The treatment team decides to cross-titrate to a
second-generation antipsychotic with a lower metabolic risk profile.
SECTION I: Index Case Analysis & Antipsychotic Selection
(Questions 1–20)
Question 1: Based on the index clinical vignette, which of the
following second-generation antipsychotics (SGAs) represents the
optimal choice for this patient given his prominent weight gain,
suboptimal glycemic control (HbA1c 8.6%), and chronic
schizophrenia?
A. Olanzapine
B. Clozapine
C. Aripiprazole
, D. Quetiapine
Rationale: Aripiprazole is a partial dopamine D2 and serotonin 5-
HT1A agonist with a neutral-to-favorable metabolic profile, making it
an excellent choice for patients with type 2 diabetes and olanzapine-
induced weight gain. Olanzapine and clozapine carry the highest
metabolic risk (weight gain, dyslipidemia, insulin resistance).
Quetiapine also carries moderate-to-high metabolic risk.
Question 2: When planning a cross-titration from olanzapine 20 mg
daily to aripiprazole for this 52-year-old male, which of the
following pharmacological principles is most critical to manage
during the transition?
A. Immediate cessation of olanzapine to prevent pharmacokinetic
interactions
B. Gradual downward titration of olanzapine while upward
titrating aripiprazole to prevent rebound psychosis and
dopaminergic supersensitivity
C. Doubling the starting dose of aripiprazole due to enzyme induction
by olanzapine
D. Adding high-potency first-generation antipsychotics for rapid
stabilization
Rationale: Cross-titration involves gradually tapering the current
agent while simultaneously initiating and titrating the new agent. This
prevents withdrawal symptoms, rebound psychosis, and acute
symptom exacerbation while monitoring for tolerability.
,Question 3: What is the primary pharmacodynamic mechanism
responsible for olanzapine's high propensity for significant weight
gain and metabolic dysregulation compared to other second-
generation antipsychotics?
A. High affinity antagonism at dopamine D2 receptors
B. Potent antagonism at histamine H1 and serotonin 5-HT2C
receptors
C. High affinity agonism at muscarinic M1 receptors
D. Potent inhibition of cytochrome P450 2D6
Rationale: Olanzapine's high binding affinity and antagonism at
histamine H1 receptors and serotonin 5-HT2C receptors are strongly
correlated with increased appetite, satiety disruption, and
downstream metabolic alterations including weight gain and insulin
resistance.
Question 4: Given the patient's baseline HbA1c elevation to 8.6%,
which baseline metabolic monitoring parameters should be
systematically evaluated before and during antipsychotic switching
according to ADA/APA consensus guidelines?
A. Complete blood count and liver function tests only
B. Fasting plasma glucose or HbA1c, fasting lipid profile, weight,
height, waist circumference, and blood pressure
C. Thyroid panel and serum electrolytes alone
D. Electroencephalogram and prolactin levels
, Rationale: The ADA/APA consensus guidelines recommend baseline
and regular monitoring of weight, waist circumference, blood
pressure, fasting plasma glucose (or HbA1c), and fasting lipid
profiles when initiating or switching antipsychotics.
Question 5: If the treatment team instead selected lurasidone for
this patient, what key pharmacokinetic instruction must be
provided regarding its administration?
A. Must be taken on an empty stomach to ensure maximum
absorption
B. Must be administered with a meal of at least 350 calories to
ensure adequate systemic bioavailability
C. Must be crushed and mixed with acidic beverages
D. Should be administered strictly once weekly via oral depot
Rationale: Lurasidone exhibits significantly increased systemic
absorption and bioavailability when ingested with food (specifically a
meal containing at least 350 calories). Administration on an empty
stomach reduces its absorption by up to 50%.
Question 6: Which of the following second-generation antipsychotics
shares a metabolic profile characterized by minimal weight gain and
a low risk of dyslipidemia, similar to aripiprazole?
A. Ziprasidone
B. Olanzapine
C. Quetiapine
PSYCHOPHARMACOLOGY & COMPREHENSIVE
BOARD REVIEW EXAMINATION
200 Clinical Questions with In-Depth Rationales
Focus: Schizophrenia, Metabolic Comorbidities, Antipsychotic Switch
Strategies, and Psychopharmacology
PRIMARY CLINICAL VIGNETTE
A 52-year-old male with chronic schizophrenia and type 2 diabetes
mellitus is currently taking olanzapine 20 mg daily with suboptimal
symptom control and a 15-kg weight gain (HbA1c increased from
7.2% to 8.6%). The treatment team decides to cross-titrate to a
second-generation antipsychotic with a lower metabolic risk profile.
SECTION I: Index Case Analysis & Antipsychotic Selection
(Questions 1–20)
Question 1: Based on the index clinical vignette, which of the
following second-generation antipsychotics (SGAs) represents the
optimal choice for this patient given his prominent weight gain,
suboptimal glycemic control (HbA1c 8.6%), and chronic
schizophrenia?
A. Olanzapine
B. Clozapine
C. Aripiprazole
, D. Quetiapine
Rationale: Aripiprazole is a partial dopamine D2 and serotonin 5-
HT1A agonist with a neutral-to-favorable metabolic profile, making it
an excellent choice for patients with type 2 diabetes and olanzapine-
induced weight gain. Olanzapine and clozapine carry the highest
metabolic risk (weight gain, dyslipidemia, insulin resistance).
Quetiapine also carries moderate-to-high metabolic risk.
Question 2: When planning a cross-titration from olanzapine 20 mg
daily to aripiprazole for this 52-year-old male, which of the
following pharmacological principles is most critical to manage
during the transition?
A. Immediate cessation of olanzapine to prevent pharmacokinetic
interactions
B. Gradual downward titration of olanzapine while upward
titrating aripiprazole to prevent rebound psychosis and
dopaminergic supersensitivity
C. Doubling the starting dose of aripiprazole due to enzyme induction
by olanzapine
D. Adding high-potency first-generation antipsychotics for rapid
stabilization
Rationale: Cross-titration involves gradually tapering the current
agent while simultaneously initiating and titrating the new agent. This
prevents withdrawal symptoms, rebound psychosis, and acute
symptom exacerbation while monitoring for tolerability.
,Question 3: What is the primary pharmacodynamic mechanism
responsible for olanzapine's high propensity for significant weight
gain and metabolic dysregulation compared to other second-
generation antipsychotics?
A. High affinity antagonism at dopamine D2 receptors
B. Potent antagonism at histamine H1 and serotonin 5-HT2C
receptors
C. High affinity agonism at muscarinic M1 receptors
D. Potent inhibition of cytochrome P450 2D6
Rationale: Olanzapine's high binding affinity and antagonism at
histamine H1 receptors and serotonin 5-HT2C receptors are strongly
correlated with increased appetite, satiety disruption, and
downstream metabolic alterations including weight gain and insulin
resistance.
Question 4: Given the patient's baseline HbA1c elevation to 8.6%,
which baseline metabolic monitoring parameters should be
systematically evaluated before and during antipsychotic switching
according to ADA/APA consensus guidelines?
A. Complete blood count and liver function tests only
B. Fasting plasma glucose or HbA1c, fasting lipid profile, weight,
height, waist circumference, and blood pressure
C. Thyroid panel and serum electrolytes alone
D. Electroencephalogram and prolactin levels
, Rationale: The ADA/APA consensus guidelines recommend baseline
and regular monitoring of weight, waist circumference, blood
pressure, fasting plasma glucose (or HbA1c), and fasting lipid
profiles when initiating or switching antipsychotics.
Question 5: If the treatment team instead selected lurasidone for
this patient, what key pharmacokinetic instruction must be
provided regarding its administration?
A. Must be taken on an empty stomach to ensure maximum
absorption
B. Must be administered with a meal of at least 350 calories to
ensure adequate systemic bioavailability
C. Must be crushed and mixed with acidic beverages
D. Should be administered strictly once weekly via oral depot
Rationale: Lurasidone exhibits significantly increased systemic
absorption and bioavailability when ingested with food (specifically a
meal containing at least 350 calories). Administration on an empty
stomach reduces its absorption by up to 50%.
Question 6: Which of the following second-generation antipsychotics
shares a metabolic profile characterized by minimal weight gain and
a low risk of dyslipidemia, similar to aripiprazole?
A. Ziprasidone
B. Olanzapine
C. Quetiapine
